Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2016, Article ID 1523691, 9 pages
http://dx.doi.org/10.1155/2016/1523691
Research Article

Investigation of Calcium Channel Blockers as Antiprotozoal Agents and Their Interference in the Metabolism of Leishmania (L.) infantum

1Centre for Parasitology and Mycology, Institute Adolfo Lutz, Secretary of Health of São Paulo State, Avenida Dr. Arnaldo 351, 01246-000 São Paulo, SP, Brazil
2Departamento de Morfologia e Patologia Básica, Faculdade de Medicina de Jundiaí, Rua Francisco Telles 250, 13202-550 Jundiai, SP, Brazil

Received 28 October 2015; Accepted 24 December 2015

Academic Editor: Juntra Karbwang

Copyright © 2016 Juliana Quero Reimão et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. P. de Menezes, C. E. Guedes, A. L. Petersen, D. B. Fraga, and P. S. Veras, “Advances in development of new treatment for leishmaniasis,” BioMed Research International, vol. 2015, Article ID 815023, 11 pages, 2015. View at Publisher · View at Google Scholar
  2. E. M. Moore and D. N. Lockwood, “Treatment of visceral leishmaniasis,” Journal of Global Infectious Diseases, vol. 2, no. 2, pp. 151–158, 2010. View at Publisher · View at Google Scholar
  3. D. R. Abernethy and J. B. Schwartz, “Calcium-antagonist drugs,” The New England Journal of Medicine, vol. 341, no. 19, pp. 1447–1457, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Motro, J. Shemesh, and E. Grossman, “Coronary benefits of calcium antagonist therapy for patients with hypertension,” Current Opinion in Cardiology, vol. 16, no. 6, pp. 349–355, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Palit and N. Ali, “Oral therapy with amlodipine and lacidipine, 1,4-dihydropyridine derivatives showing activity against experimental visceral leishmaniasis,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 1, pp. 374–377, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. A. G. Tempone, N. N. Taniwaki, and J. Q. Reimão, “Antileishmanial activity and ultrastructural alterations of Leishmania (L.) chagasi treated with the calcium channel blocker nimodipine,” Parasitology Research, vol. 105, no. 2, pp. 499–505, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Q. Reimão, M. T. Scotti, and A. G. Tempone, “Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: in vitro evaluation and structure-activity relationship study,” Bioorganic and Medicinal Chemistry, vol. 18, no. 22, pp. 8044–8053, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. R. A. M. Williams, T. K. Smith, B. Cull, J. C. Mottram, and G. H. Coombs, “ATG5 is essential for ATG8-dependent autophagy and mitochondrial homeostasis in Leishmania major,” PLoS Pathogens, vol. 8, no. 5, Article ID e1002695, 14 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. J. T. Mesquita, E. G. Pinto, N. N. Taniwaki, A. J. Galisteo Jr., and A. G. Tempone, “Lethal action of the nitrothiazolyl-salicylamide derivative nitazoxanide via induction of oxidative stress in Leishmania (L.) infantum,” Acta Tropica, vol. 128, no. 3, pp. 666–673, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. M. L. Mangoni, J. M. Saugar, M. Dellisanti, D. Barra, M. Simmaco, and L. Rivas, “Temporins, small antimicrobial peptides with leishmanicidal activity,” The Journal of Biological Chemistry, vol. 280, no. 2, pp. 984–990, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. Q. L. Fivelman, I. S. Adagu, and D. C. Warhurst, “Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 11, pp. 4097–4102, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Q. Reimão and A. G. Tempone, “Investigation into in vitro anti-leishmanial combinations of calcium channel blockers and current anti-leishmanial drugs,” Memórias do Instituto Oswaldo Cruz, vol. 106, no. 8, pp. 1032–1038, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. F. C. Odds, “Synergy, antagonism, and what the chequerboard puts between them,” Journal of Antimicrobial Chemotherapy, vol. 52, no. 1, article 1, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Seifert, J. Munday, T. Syeda, and S. L. Croft, “In vitro interactions between sitamaquine and amphotericin B, sodium stibogluconate, miltefosine, paromomycin and pentamidine against Leishmania donovani,” Journal of Antimicrobial Chemotherapy, vol. 66, no. 4, Article ID dkq542, pp. 850–854, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. A. G. Tempone, R. A. Mortara, H. F. de Andrade, and J. Q. Reimão, “Therapeutic evaluation of free and liposome-loaded furazolidone in experimental visceral leishmaniasis,” International Journal of Antimicrobial Agents, vol. 36, no. 2, pp. 159–163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Q. Reimão, F. A. Colombo, V. L. Pereira-Chioccola, and A. G. Tempone, “In vitro and experimental therapeutic studies of the calcium channel blocker bepridil: detection of viable Leishmania (L.) chagasi by real-time PCR,” Experimental Parasitology, vol. 128, no. 2, pp. 111–115, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. L. M. Johansen, L. E. DeWald, C. J. Shoemaker et al., “A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity,” Science Translational Medicine, vol. 7, no. 290, pp. 1–14, 2015. View at Publisher · View at Google Scholar
  18. G. Gehring, K. Rohrmann, N. Atenchong et al., “The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry,” Journal of Antimicrobial Chemotherapy, vol. 69, no. 8, pp. 2123–2131, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. A. P. De Souza, H. B. Tanowitz, M. Chandra et al., “Effects of early and late verapamil administration on the development of cardiomyopathy in experimental chronic Trypanosoma cruzi (Brazil strain) infection,” Parasitology Research, vol. 92, no. 6, pp. 496–501, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. L. J. Núñez-Vergara, J. A. Squella, S. Bollo-Dragnic et al., “Isradipine and lacidipine: effects in vivo and in vitro on Trypanosoma cruzi epimastigotes,” General Pharmacology, vol. 30, no. 1, pp. 85–87, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. L. J. Núñez-Vergara, J. A. Squella, S. Bollo-Dragnic et al., “Nitro aryl 1,4-dihydropyridine derivatives: effects on Trypanosoma cruzi,” Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology, vol. 118, no. 1, pp. 105–111, 1997. View at Publisher · View at Google Scholar · View at Scopus
  22. V. Masseno, S. Muriithi, and A. Nzila, “In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 7, pp. 3131–3134, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. K. S. Moshal, J. S. Adhikari, K. Bist et al., “Calcium hannel antagonist (nifedipine) attenuates Plasmodium berghei-specific T cell immune responses in Balb/C mice,” Acta Pathologicam Microbiologica et Immunologica Scandinavica, vol. 115, no. 8, pp. 911–920, 2007. View at Publisher · View at Google Scholar
  24. A. Ponte-Sucre, Y. Campos, M. Fernandez, H. Moll, and A. Mendoza-León, “Leishmania sp.: growth and survival are impaired by ion channel blockers,” Experimental Parasitology, vol. 88, no. 1, pp. 11–19, 1998. View at Publisher · View at Google Scholar · View at Scopus
  25. Z. Dong, P. Saikumar, J. M. Weinberg, and M. A. Venkatachalam, “Calcium in cell injury and death,” Annual Review of Pathology, vol. 1, pp. 405–434, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Benaim, Y. García-Marchán, C. Reyes, G. Uzcanga, and K. Figarella, “Identification of a sphingosine-sensitive Ca2+ channel in the plasma membrane of Leishmania mexicana,” Biochemical and Biophysical Research Communications, vol. 430, no. 3, pp. 1091–1096, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Carvalho, J. R. Luque-Ortega, J. I. Manzano, S. Castanys, L. Rivas, and F. Gamarro, “Tafenoquine, an antiplasmodial 8-aminoquinoline, targets Leishmania respiratory complex III and induces apoptosis,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 12, pp. 5344–5351, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. R. F. S. Menna-Barreto and S. L. de Castro, “The double-edged sword in pathogenic trypanosomatids: the pivotal role of mitochondria in oxidative stress and bioenergetics,” BioMed Research International, vol. 2014, Article ID 614014, 14 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Fonseca-Silva, J. D. F. Inacio, M. M. Canto-Cavalheiro, and E. E. Almeida-Amaral, “Reactive oxygen species production and mitochondrial dysfunction contribute to quercetin induced death in Leishmania amazonensis,” PLoS ONE, vol. 6, no. 2, Article ID e14666, pp. 1–7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. C.-W. Wang, C.-K. Wang, Y.-J. Chang et al., “Preclinical evaluation on the tumor suppression efficiency and combination drug effects of fermented wheat germ extract in human ovarian carcinoma cells,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 570785, 8 pages, 2015. View at Publisher · View at Google Scholar
  31. G. Polanco-Hernández, F. Escalante-Erosa, K. García-Sosa et al., “Synergistic effect of lupenone and caryophyllene oxide against Trypanosoma cruzi,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 435398, 6 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Berg, R. García-Hernández, B. Cuypers et al., “Experimental resistance to drug combinations in Leishmania donovani: metabolic and phenotypic adaptations,” Antimicrobial Agents and Chemotherapy, vol. 59, no. 4, pp. 2242–2255, 2015. View at Publisher · View at Google Scholar
  33. R. J. Tallarida, “An overview of drug combination analysis with isobolograms,” Journal of Pharmacology and Experimental Therapeutics, vol. 319, no. 1, pp. 1–7, 2006. View at Publisher · View at Google Scholar · View at Scopus